New 'Reference Regimen' in Metastatic Pancreatic Cancer? : c

Liposomal irinotecan plus chemo in the new NALIRIFOX regimen significantly improved overall survival compared with standard therapy in metastatic pancreatic ductal adenocarcinoma.

Related Keywords

California , United States , Tennessee , Los Angeles , America , Zeva Wainberg , Laura Goff , Daiichi Sankyo Astra Zeneca , Astrazeneca Medimmune , Bristol Myers Squibb , University Of California , Amgen , Genentech , Boehringer Ingelheim , Novartis , Pfizer , Ucla Gi Oncology Program , Astrazeneca , North America , Cancer Patient Care Center , Vanderbilt Ingram Cancer Center , Arcus Bioscience , Astra Zeneca , Malignant Pancreatic Neoplasm , Pancreatic Cancer , Ancer Pancreatic , Pancreatic Adenocarcinoma , Denocarcinoma Of The Pancreas , Adenocarcinoma , Malignant Secondary Liver Neoplasm , Etastasis Liver , Hepatocellular Carcinoma , Liver Cancer , Dcc , Hepatocellular Cancer , Ancer Liver , Ancer Hepatocellular , Metastasis , Cancer , Alignant Neoplasia , Arcinoma , Chemotherapy , Pancreas , Tumor ,